Health Condition 1: null- diffuse large B cell lymphoma Health Condition 2: C833- Diffuse large B-cell lymphoma
Conditions
Interventions
Intervention1: Involved site radiation 30 Gy in 15 fractions: Persons randomised to radiation arm at least 4 weeks after last cycle of chemotherapy (but not later than 8 weeks). Involved site Radiatio
Sponsors
Cancer Institute WIA
Eligibility
Inclusion criteria
Inclusion criteria: Adult patients with diagnosis Diffuse large B cell lymphoma with stage I-II disease (staged at the baseline with PET –CT/ CECT of the chest, abdomen and pelvis) and achieving a good response by PET-CT imaging after first-line chemotherapy Good response is defined as residual masses =2 cm AND Deauville score of =2 on the end therapy scan performed at least 3 weeks after last cycle of chemotherapy Included patients must have received at least 4 cycles (for non-bulky 1. Age =18 years 2. Adequate data available regarding baseline diagnosis (including histopathology with IHC) as well as details of chemotherapy delivered and dose compromises if any and reasons for the same. 3. Performance status of 0-2 at the time of randomisation 4. Recovered from toxicity of chemotherapy, especially hematological toxicity 5. Willing to provide informed consent for the trial. 6. Women in the reproductive age group must agree to be on effective contraception during the period of radiation.
Exclusion criteria
Exclusion criteria: 1. >8 weeks delay from the last cycle of chemotherapy to the randomization 2. HIV/HBsAg/HCV positivity 3. Primary mediastinal B cell lymphoma, Primary CNS lymphoma. 4. Uncontrolled medical illnesses which could compromise the delivery of radiation therapy. 5. Pregnant females will be excluded. 6. History of malignancy treated within the last 5 years. 7. Any other contraindication to radiation therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event Free SurvivalTimepoint: 5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survivalTimepoint: 5 years;Relapse free survivalTimepoint: 5 years;Toxicity, acuteTimepoint: 6 months;Toxicity, delayedTimepoint: 5 years | — |
Countries
India
Contacts
Public ContactPrasanth Ganesan
Cancer Institute (WIA)
Outcome results
None listed